These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 36813538)

  • 61. Subsequent biologic and targeted synthetic disease modifying anti rheumatic drugs after fulfilling difficult-to-treat rheumatoid arthritis criteria: a survival analysis.
    Novella-Navarro M; Ruiz-Esquide V; López-Juanes N; Chacur CA; Monjo-Henry I; Nuño L; Peiteado D; Villalba A; Fernández-Fernandez E; Sanz-Jardón M; Kafati M; Sanmartí R; Plasencia-Rodríguez C; Balsa A
    Clin Rheumatol; 2024 Sep; 43(9):2817-2823. PubMed ID: 39009920
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
    Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
    Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
    [TBL] [Abstract][Full Text] [Related]  

  • 63. An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naïve patients with psoriatic arthritis.
    Betts KA; Griffith J; Friedman A; Zhou ZY; Signorovitch JE; Ganguli A
    Curr Med Res Opin; 2016; 32(4):721-9. PubMed ID: 26743448
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
    Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW
    J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis.
    McInnes IB; Nash P; Ritchlin C; Choy EH; Kanters S; Thom H; Gandhi K; Pricop L; Jugl SM
    J Comp Eff Res; 2018 Nov; 7(11):1107-1123. PubMed ID: 30230361
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy of new treatments for dactylitis of psoriatic arthritis: update of literature review.
    Sondag M; Verhoeven F; Guillot X; Prati C; Wendling D
    Clin Rheumatol; 2019 Feb; 38(2):591-596. PubMed ID: 30328022
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study.
    Jeong S; Choi S; Park SM; Kim J; Ghang B; Lee EY
    Arthritis Res Ther; 2022 Jul; 24(1):180. PubMed ID: 35902964
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis.
    Mease PJ; Gladman DD; Merola JF; Nash P; Grieve S; Laliman-Khara V; Willems D; Taieb V; Prickett AR; Coates LC
    Rheumatology (Oxford); 2024 Jul; 63(7):1779-1789. PubMed ID: 38218744
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Infection outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study.
    Simon TA; Suissa S; Skovron ML; Frisell T; Askling J; Michaud K; Pedro S; Strangfeld A; Meissner Y; Boers M; Hoffman V; Dominique A; Gomez A; Hochberg MC
    Semin Arthritis Rheum; 2024 Feb; 64():152313. PubMed ID: 38044241
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
    Strand V; de Vlam K; Covarrubias-Cobos JA; Mease PJ; Gladman DD; Graham D; Wang C; Cappelleri JC; Hendrikx T; Hsu MA
    RMD Open; 2019; 5(1):e000806. PubMed ID: 30713721
    [TBL] [Abstract][Full Text] [Related]  

  • 71. New targets in psoriatic arthritis.
    Braun J
    Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii30-ii37. PubMed ID: 27856658
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
    Rodgers M; Epstein D; Bojke L; Yang H; Craig D; Fonseca T; Myers L; Bruce I; Chalmers R; Bujkiewicz S; Lai M; Cooper N; Abrams K; Spiegelhalter D; Sutton A; Sculpher M; Woolacott N
    Health Technol Assess; 2011 Feb; 15(10):i-xxi, 1-329. PubMed ID: 21333232
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results.
    Smolen JS; Siebert S; Korotaeva TV; Selmi C; Bergmans P; Gremese E; Joven-Ibáñez B; Katsifis G; Noël W; Nurmohamed MT; Richette P; Sfikakis PP; de Vlam K; Theander E; Gossec L
    Ann Rheum Dis; 2021 Nov; 80(11):1419-1428. PubMed ID: 34162594
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Real-World Persistence and Treatment Patterns in Patients with Psoriatic Arthritis Treated with Anti-IL17 Therapy in Spain: The PerfIL-17 Study.
    Joven B; Manteca CF; Rubio E; Raya E; Pérez A; Hernández R; Manrique S; Núñez M; Díaz-Cerezo S; Moyano S; Lacetera A; García-Vicuña R
    Adv Ther; 2023 Dec; 40(12):5415-5431. PubMed ID: 37804475
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry.
    Jung JY; Lee E; Kim JW; Suh CH; Shin K; Kim J; Kim HA
    Arthritis Res Ther; 2023 Sep; 25(1):174. PubMed ID: 37726808
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.
    Singh JA; Guyatt G; Ogdie A; Gladman DD; Deal C; Deodhar A; Dubreuil M; Dunham J; Husni ME; Kenny S; Kwan-Morley J; Lin J; Marchetta P; Mease PJ; Merola JF; Miner J; Ritchlin CT; Siaton B; Smith BJ; Van Voorhees AS; Jonsson AH; Shah AA; Sullivan N; Turgunbaev M; Coates LC; Gottlieb A; Magrey M; Nowell WB; Orbai AM; Reddy SM; Scher JU; Siegel E; Siegel M; Walsh JA; Turner AS; Reston J
    Arthritis Rheumatol; 2019 Jan; 71(1):5-32. PubMed ID: 30499246
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.
    Choquette D; Bessette L; Alemao E; Haraoui B; Postema R; Raynauld JP; Coupal L
    Arthritis Res Ther; 2019 Jun; 21(1):138. PubMed ID: 31171024
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
    Rotar Ž; Tomšič M; Praprotnik S;
    Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Treat-to-target in real-life psoriatic arthritis patients: achieving minimal disease activity with bDMARDs/tsDMARDs and potential barriers.
    Ortolan A; Lorenzin M; Cozzi G; Scagnellato L; Favero M; Striani G; Vio S; Scapin V; De Conti G; Doria A; Ramonda R
    Semin Arthritis Rheum; 2023 Oct; 62():152237. PubMed ID: 37453183
    [TBL] [Abstract][Full Text] [Related]  

  • 80. How has the COVID-19 pandemic affected our rheumatology patients using biological/targeted DMARDs?
    Gulle S; Erez Y; Karakas A; Yuce Inel T; Kocaer SB; Demirci Yildirim T; Can G; Sari I; Birlik M; Onen F
    J Infect Dev Ctries; 2023 Jul; 17(7):944-952. PubMed ID: 37515801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.